Late Breaking Abstract - Prevalence of new frailty and its associated factors in severe covid-19 survivors

<bold>Background:</bold> Development of frailty at hospital discharge affects clinical outcomes in in critically ill survivors with COVID-19 who had no frailty before hospitalization. <bold>Objective:</bold> Describe the prevalence of new frailty using clinical frailty scale (CFS) and evaluate its associated factors in critically ill survivors with COVID-19 who never had pre-hospitalization frailty. <bold>Methods:</bold> Clinical data of nationwide retrospective cohort collected from 22 hospitals during January 1 2020 thorough Augus 31 2021 were secondarily analyzed. Patients were at least 19 years old and survived to discharge after admission to ICU due to severe COVID-19. Development of new frailty was defined as CFS was 5 or greater at hospital discharge. <bold>Results:</bold> Among 669 critically ill and non-frail patients with COVID-19 who admitted to ICU and survived at discharge, mean age was 65.2 ± 12.8 year old and the male sex was 62.5%. 50.2% patients received mechanical ventilation. Mean CFS of total patients at admission was 2.4 ± 0.9. New frailty developed in 27.8% (186/483). Patients with new frailty were older and had more comorbidities. They also stayed longer in ICU and hospital compared to those without frailty. In multivariable analysis, older age, cardiovascular disease, CFS 3-4 before hospitalization, increased C reactive protein, longer duration of treatment of corticosteroid, use of MV and ECMO were identified as associated factors for new frailty. <bold>Conclusion:</bold> New frailty at hospital discharge is common and associated with several modifiable factors in critically ill patients with severe COVID-19.